Drug intelligence / Profile preview

BAY987518

Development stage: Phase 1
Lead developer: Bayer
Modality: Small Molecules
Administration: Topical

Overview

BAY987518 is a research compound developed by Bayer. It is described as a sunscreening agent and has been investigated in clinical studies involving healthy volunteers. The specific mechanism of action and molecular target are not detailed in the available sources, but it is classified as a sunscreening agent, suggesting its primary use may be for topical photoprotection or UV filtering. There is no evidence that it has reached advanced clinical development or approval stages[1][3][4].

Beyond the preview

Go deeper on BAY987518.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAY987518.

Explore the full profile